Abstract
In Lyme disease (LD), 10-20% of patients develop persistent symptoms following antibiotic treatment (i.e., post-treatment Lyme disease (PTLD)), which often includes neurological symptoms. This study tested the hypothesis that brain changes occur early in LD and influence outcomes.
Functional MRI (fMRI) of working memory and health surveys were administered to people with acute LD (n=20) after treatment and six months later. Demographically matched healthy controls (HC; n=19) were also assessed six months apart. The LD group was categorized at six months into those who had returned to health (RTH, n=11) or reported persistent symptoms (sPTLD, n=9). FMRI data from both LD subgroups were compared to each other and HC at both time points. Brain regions of interest (ROI) values were compared to health surveys.
Baseline brain activity in RTH was elevated in fronto-parietal regions relative to sPTLD (p < .0025) and HC (p < .001). Notably, 64% of activation clusters in RTH were in white matter, confirmed by segmentation analysis. ROI values from RTH vs. HC correlated with higher health survey scores. At 6-months, few group differences remained. By contrast, ROI values from sPTLD vs. HC yielded few activation differences at either time point or correlations with health survey scores.
Robust brain activity in early LD was associated with future RTH. By contrast, the absence of early brain activity was associated with persistent symptoms, suggesting that failure to mount an early response contributes to PTLD. Understanding how brain activity relates to recovery in LD can aid prognosis and guide treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by P-Squared Philanthropies, Inc. The MRI equipment in this study was funded by NIH grant 1S10ODO21648. This project described was also supported by Grant Number UL1 RR 025005 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the Johns Hopkins University School of Medicine approved this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The Methods section was clarified to define criteria used for RTH and sPTLD definitions. The Discussion section added alternative interpretations for white matter event-related activations observed in the RTH vs. HC comparisons.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
